FDA Officials Eye AI Integration In Clinical Trials, Grapple With Bias Concerns

FDA’s medical policy chief signals that the agency is open to various uses of artificial intelligence, including integrating the technology into the design and conduct of clinical trials. At the same time, FDA and other health agencies are grappling with how to ensure the data in AI models don’t reproduce bias or produce recommendations that can’t be explained. The remarks by the drug center official cast a more optimistic light than recent statements by the FDA commissioner and biologics center...